Fort Wayne, INNCT05602363Now EnrollingIRB Ready

B-cell Malignancy Clinical Trial in Fort Wayne, IN

Access cutting-edge b-cell malignancy treatment through this clinical trial at a research site in Fort Wayne. Study-provided care at no cost to qualified participants.

Sponsored by Carna Biosciences, Inc.

Quick Self-Assessment

See if you qualify for this Fort Wayne location

Preparing your pre-screening questions…

Expert Care in Fort Wayne

Access b-cell malignancy specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related b-cell malignancy treatment provided free

Apply for This Fort Wayne Location

Check if you qualify for this b-cell malignancy clinical trial in Fort Wayne, IN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Fort Wayne

    Convenient for IN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Fort Wayne site if eligible
  4. 4Begin participation

About This B-cell Malignancy Study in Fort Wayne

This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

Sponsor: Carna Biosciences, Inc.

Who Can Participate

Inclusion Criteria

Age ≥18 years
Provided written informed consent
Histologically confirmed B-cell malignancy, including CLL/SLL, WM, MCL, MZL, or FL
Patients with SLL, MCL, MZL, and FL: at least 1 radiographically measurable lesion
Failed or are intolerant to ≥2 prior lines of systemic therapy
ECOG Performance Status 0 to 2
Adequate hematologic status (ie, absolute neutrophil count ≥0.75 × 10⁹/L, platelet count ≥50 × 10⁹/L, hemoglobin ≥8 g/dL) not requiring transfusion support or growth factors
Adequate hepatic function
Adequate renal function
Ability to swallow tablets and comply with study requirements for the duration of study participation
Male and female patients of reproductive potential: Willing to observe conventional and effective birth control methods
Male patients: agree not to donate sperm during and for 6 months after the study
Dose Expansion Cohort 3 patients: prior treatment with pirtobrutinib (Jaypirca) for an approved indication

Exclusion Criteria

Transformed disease (eg, Richter's transformation) prior to or during Screening
Investigational agent or anticancer therapy within 5 half-lives before the planned start of docirbrutinib, except therapeutic monoclonal antibody treatment which must be discontinued at least 4 weeks before the start of docirbrutinib
Current treatment with investigational therapy or planned investigational therapy which would be concurrent with this study
Requiring therapeutic anticoagulation with warfarin
Current treatment with certain strong CYP3A4 inhibitors or inducers
Treatment with proton pump inhibitors within 7 days before first dose of docirbrutinib
Current treatment with strong P-glycoprotein inhibitors or strong BCRP inhibitors
Refractory to transfusion support
Major surgery within 4 weeks before planned start of docirbrutinib
Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment
Any unresolved toxicities from prior therapy greater than NCI CTCAE Version 5.0 Grade 2 at the time of starting study treatment except for alopecia
History of allogeneic or autologous stem cell transplant or CAR-T therapy within the last 30 days
Active second malignancy unless in remission with life expectancy \>2 years
Known central nervous system (CNS) involvement by systemic lymphoma
Active uncontrolled autoimmune cytopenia (eg, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura) where new therapy introduced or concomitant therapy escalated within the 4 weeks before study enrollment is required to maintain adequate blood counts
Clinically significant, uncontrolled cardiac, cardiovascular disease or history of myocardial infarction within 6 months before planned start of docirbrutinib, or prolongation of the QT interval corrected for heart rate using Fridericia's Formula (QTcF) \>470 msec on at least 2 of 3 consecutive ECGs, and mean QTcF \>470 msec on all 3 ECGs, during Screening
Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
Positive for HIV. For patients with unknown HIV status, HIV testing will be performed at Screening
Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of docirbrutinib
Pregnant or lactating.
Known hypersensitivity to any component or excipient of docirbrutinib
Prior treatment with docirbrutinib
Dose Escalation and Cohort 3 patients: prior treatment with noncovalent BTKi except pirtobrutinib (Jaypirca)
Dose Expansion Cohort 1 and Cohort 2 patients: prior treatment with any noncovalent BTKi

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Fort Wayne?

Yes, this clinical trial (NCT05602363) has an active research site in Fort Wayne, IN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

B-cell Malignancy Treatment Options in Fort Wayne, IN

If you're searching for b-cell malignancy treatment options in Fort Wayne, IN, this clinical trial (NCT05602363) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Fort Wayne research site is actively enrolling participants for this clinical trial. You'll receive care from experienced b-cell malignancy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Ready to Join in Fort Wayne?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Fort Wayne, IN